Nanobiotix Announces Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 In Locally Advanced Head And Neck Cancer Showing Median Progression-Free Survival Of 16.9 Months And Median Overall Survival Of 23.1 Months
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix has announced the final efficacy analysis from its Phase 1 cohort expansion evaluating NBTXR3 in locally advanced head and neck cancer. The results show a median progression-free survival of 16.9 months and median overall survival of 23.1 months. The study found that NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity. Compared with historical data, these results potentially strengthen the hypothesis and clarify next steps for the ongoing global, Phase 3 study evaluating NBTXR3.
October 04, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix's Phase 1 study results show promising efficacy of NBTXR3 in treating head and neck cancer, potentially strengthening the case for its ongoing Phase 3 study.
The positive results from the Phase 1 study of NBTXR3 show its potential efficacy in treating head and neck cancer. This could strengthen the case for its ongoing Phase 3 study, potentially leading to regulatory approval and commercialization, which would likely have a positive impact on Nanobiotix's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100